Epitalon vs pinealon
Epitalon and pinealon are short synthetic peptides from the same Russian bioregulator research program, a tetrapeptide and a tripeptide respectively. This page compares their sequences, origins, proposed mechanisms, evidence quality, regulatory status and analytical concerns.
Epitalon (Ala-Glu-Asp-Gly) and pinealon (Glu-Asp-Arg) come from the research network led by Vladimir Khavinson in St Petersburg, which has proposed that very short peptides act as tissue-specific bioregulators. Epitalon was designed as a synthetic counterpart to epithalamin, a peptide extract of bovine pineal gland. Pinealon was later proposed as a bioregulator associated with brain tissue.
Because both are associated with pineal research and with aging, they are often listed together. Their evidence bases differ in size but share the same limitation: most studies come from one research network, and independent replication and controlled human trials are lacking. Epitalon was reviewed by the FDA's compounding advisory committee in July 2026; pinealon was not.
Side-by-side
| Attribute | Epitalon | Pinealon |
|---|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG) | Glu-Asp-Arg (EDR) |
| Length | 4 residues | 3 residues |
| Origin | Synthetic analogue based on epithalamin, a pineal gland extract | Synthetic; proposed by the same group as a brain-associated bioregulator |
| Proposed mechanism | Telomerase activation and gene-expression effects in cell culture; melatonin rhythm effects (proposed) | Antioxidant and gene-expression effects in neural cells (proposed) |
| Research areas | Telomeres in cultured cells; rodent lifespan and tumor studies; circadian rhythms | Oxidative stress in cultured cells; rodent hypoxia and stress models |
| Evidence level | Early-clinical; small, mostly non-randomized human studies | Preclinical; human evidence absent or limited |
| FDA / compounding | Not FDA-approved; PCAC voted in July 2026 to recommend 503A bulk listing, no final FDA action | Not FDA-approved; not part of the July 2026 PCAC vote |
| WADA | Check the current WADA Prohibited List | Check the current WADA Prohibited List |
| Analytical pitfalls | Asp-Gly aspartimide and isoaspartate formation; counter-ion share of mass | Asp isomerization; very high counter-ion share of mass; poor HPLC retention |
| Storage | Lyophilized at -20 °C, protected from moisture; avoid freeze-thaw | Lyophilized at -20 °C, protected from moisture; avoid freeze-thaw |
Shared origin, different targets
Both peptides reflect the bioregulator hypothesis, which holds that short peptides isolated from or modeled on specific tissues can influence gene expression in those tissues. Epitalon was tied to the pineal gland through its link to epithalamin and has been studied mainly in relation to telomerase, melatonin and aging. Pinealon, despite its name, has been studied mostly in neural cells and brain-related animal models. The proposed mechanism of short peptides entering cells and binding DNA directly is not widely accepted outside this research network.
Evidence quality
Epitalon has the larger literature, including cell-culture telomerase studies, rodent lifespan studies and small human observational reports from Russia. Pinealon's literature is smaller and consists mainly of cell and rodent studies. For both, most reports come from one group, many are in journals with limited international reach, and results have rarely been tested by independent laboratories. Claims about longevity or neuroprotection should be treated as unconfirmed. Human evidence is limited for epitalon and essentially absent for pinealon.
Analytical considerations for very short peptides
At three and four residues, these peptides have low masses, so counter-ions and water make up a large share of a powder's weight, and net peptide content should be reported alongside HPLC purity. Both are highly polar and can elute early in standard reversed-phase HPLC, where they may be poorly separated from salts and other polar impurities. Epitalon's C-terminal Asp-Gly is prone to aspartimide and isoaspartate formation, which produces isomers of the same mass that MS alone cannot distinguish. See purity vs net peptide content.
Frequently asked questions
What is the difference between epitalon and pinealon?
Epitalon is the tetrapeptide Ala-Glu-Asp-Gly, designed after a pineal gland extract and studied mainly for telomerase and aging-related effects. Pinealon is the tripeptide Glu-Asp-Arg, studied mainly in neural cell and animal models of oxidative stress. Both come from the same Russian research network, and neither has controlled human trial evidence.
Are epitalon and pinealon FDA approved?
Neither is approved by the FDA for any use. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding epitalon to the 503A bulk drug substances list, against the recommendation of FDA's own reviewers; the vote is advisory and no final action has been announced. Pinealon was not part of that review.
Does pinealon come from the pineal gland?
Not directly. Pinealon is a synthetic tripeptide, and despite its name its published research has focused mainly on neural cells and brain-related animal models. Epitalon has the stronger connection to the pineal gland, because it was designed as a synthetic counterpart to epithalamin, a peptide preparation extracted from bovine pineal tissue.
Full entries
- Epitalon
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson's group in St. Petersburg, based on a pineal gland extract. It is studied in aging and telomere research, with evidence coming mostly from that group.
- Pinealon
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from Vladimir Khavinson's group in St. Petersburg, one of their short peptide bioregulators. It has been studied mainly in cell and animal models of neural aging and stress, with evidence mostly from that group.
Cite this page